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Please check whether the article title is OK as given in Ref. [14] . 25 day 30 postoperation. Among those with TAEs, 7 experienced cerebrovascular accidents, 2 had myocardial infarction and 1 had pulmonary embolism. A multivariable regression model confirmed rFVIIa as the only independent factor associated with the development of TAEs (odds ratio 6.19, 95% confidence interval 1.197-31.996; P = 0.0296). Fifteen (8.3%) patients were re-explored for bleeding according to our management protocol. No variables to predict the need for re-exploration were identified by the regression model. Chest tube output was statistically significantly lower in patients who received rFVIIa from 3 h [1.9 (Q1-Q3 1.7-2.1) ml/kg/h vs 3.2 (Q1-Q3 3-3.4) ml/kg/h, 30 P = 0.000] through to 12 h after admission [0.6 (Q1-Q3 0.5-0.6) ml/kg/h vs 0.7 (Q1-Q3 0.6-0.9) ml/kg/h, P = 0.000].
CONCLUSIONS: rFVIIa for the treatment of post-CABG bleeding resulted in increased incidence of TAEs in spite of rapid control of bleeding. Hence, rFVIIa should only be used in such patients within a very narrow range of suitable patients and with extreme caution. 
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INTRODUCTION
Postoperative bleeding occurs in 3-5% of cases following cardiac surgery [1] . Failure of the haemostatic pathways is the major cause, in addition to surgical bleeding. Life-threatening postoperative bleeding may persist in spite of transfusions and medical 40 therapy, and re-exploration may be required [2] . Three to four percent of patients undergoing coronary artery bypass grafting (CABG) surgery require re-exploration for bleeding, which may cause a 2-to 3-fold increase in mortality [3] . Recombinant activated factor VII (rFVIIa) was originally devel-45 oped to treat bleeding in patients with haemophilia A or B [4] .
There are reports [5] [6] [7] describing the efficacy and safety of rFVIIa in cardiac surgery but there is limited information regarding its use in CABG. On the contrary, many cardiac surgery studies and metaanalyses [8-12] report some thromboembolic adverse events 50 (TAEs), such as stroke, myocardial infarction (MI), pulmonary embolism (PE), deep venous thrombosis or any other arterial thrombosis, even though the CABG population has not been explored in detail. Hence, the aim of the present retrospective study is to evaluate the possible impact of rFVIIa administration on TAEs in a CABG 55 population presenting postoperative bleeding.
PATIENTS AND METHODS
The study was conducted in the Cardiac Surgical Intensive Care Unit (CSICU), King Faisal Heart Center, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia. Retrospectively, the medical charts of all adult patients who had undergone CABG surgery between January 2004 and May 2015 were screened to identify those who had postoperative bleeding. Postoperative bleeding was de-5 fined as chest tube bleeding of 3 ml/kg/h or greater for 2 or more consecutive hours after admission to the CSICU from the operating room. The study protocol was approved by the institutional research centre and ethics committee (RAC # 2121076). As this was a retrospective chart review study, informed consent was waived by 10 the ethical committee.
PATIENTS
Inclusion criteria
All patients in CSICU who underwent CABG surgery between January 2004 and May 2015 and experienced postoperative 15 bleeding were included in the study.
Exclusion criteria
Patients aged less than 18 years old, with a primary coagulation defect, who received rFVIIa in the operating room, pregnant females, or those requiring a mechanical circulatory support device 20 or extracorporeal membrane oxygenation were excluded.
Management of postoperative bleeding in the cardiac surgical intensive care unit and use of recombinant activated factor VII According to the intraoperative protocol, all patients received a 25 20 -mg/kg tranexamic acid bolus followed by 5 mg/kg/h during the operation and until skin closure. After the bypass, protamine was given to reverse the residual effects of heparin, aiming at an activated clotting time of 120-140 s. Figure 1 shows the management of postoperative bleeding in 30 our CSICU.
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Exclusion of surgical causes of bleeding requiring reexploration (cardiac tamponade, mediastinal haematoma or huge haemothorax) was performed by clinical examination, haemodynamic monitoring, chest X-ray and bedside echocardiography, and finally by consulting the attending cardiac surgeon. Two 35 doses of rFVIIa were commonly used in our CSICU: a full dose (90-120 mg/kg) or a half dose (40-50 mg/kg). The decision to administer rFVIIa was made after discussion between the intensive care unit and surgical teams regarding the options for further treatments, the risks associated with rFVIIa administration, the 40 likelihood of re-exploration, and the haemodynamic state, according to the protocol reported in Fig. 1 .
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Baseline assessment and data collection
Demographic and clinical data, as well as all the information to calculate EuroSCORE II (European System for Cardiac Operative 45 Risk Evaluation II) [14] , were obtained for each patient. Smoking was defined as current smoker or those who ceased smoking in the month previous to surgery. Operative data included: type of surgical procedure, cardiopulmonary bypass time (CPB), cross-clamping time and circulatory arrest 50 time. Laboratory values were recorded at hospital admission for: haemoglobin, prothrombin time, activated partial thromboplastin time, international normalized ratio, creatinine level, electrolyte levels, bilirubin level, white blood cell counts and platelet counts.
Outcome measures
55
TAEs were defined as cerebrovascular accidents (CVAs) [15] , MI [16] , PE [17] , deep venous thrombosis or arterial thrombosis. Screening for TAE was performed daily by physical examination. When TAE was suspected, the confirming diagnosis was achieved by coloured duplex ultrasonography for the suspected affected 60 site, trans-thoracic echocardiography, brain computed tomography (CT) scan or magnetic resonance imaging, pulmonary angiogram or CT angiogram and laboratory blood tests. A further brain CT scan was repeated after 48 h if there were no findings from the first scan but the clinical signs of TAEs were still present.
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Statistical analysis
Descriptive statistics for the continuous variables are reported as mean ± standard deviation for parametric data while nonparametric data are presented as median and 25th and 75th percentiles. In Supplementary Material, Table S1 , normal distribution 70 is reported.
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Categorical variables are summarized as frequencies and percentages. Comparison between the rFVIIa group and the conventional treatment group was done by Student's AQ10 independent t-test or Mann-Whitney U-test for continuous variables, while categorical variables were compared using Fisher's exact 75 test. To determine the variables associated with TAEs and reexploration in post-CABG bleeding patients, we conducted standard univariable and multivariable logistic regression analyses for each outcome. A threshold of P-value < _0.3 was chosen in the univariable models to select variables for the multivariable models.
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The discrimination and calibration of the final models were tested by receiver operating characteristic curve analysis and Hosmer-Lemeshow Test, respectively. Statistical analyses of the data were done using the software packages SAS version 9.4 (Statistical Analysis System, SAS Institute Inc., Cary, NC, USA) and 
RESULTS
Demographic and important laboratory data for the patients who received rFVIIa compared to the conventional treatment 90 group are presented in Table 1 . EuroSCORE II and white blood counts were statistically significantly higher in the conventional treatment group compared to the rFVIIa group. Seventeen percent of all patients were taking an oral anticoagulant prior surgery. All of them were shifted to low-or high-molecular-weight 95 heparin 5 days before surgery. Heparin was stopped 12 h before surgery. For emergency cases, high international normalized ratio was reversed to <1.5 using fresh frozen plasma before surgery. Around 92.8% of patients received antiplatelet drugs before surgery: all of these patients received aspirin and 16 (8.9%) patients 100 received an adenosine diphosphate receptor blocker in addition to aspirin. In all patients but emergency cases, antiplatelet drugs were discontinued 5 days before surgery. All emergency cases received aspirin and 2 of them also received adenosine diphosphate receptor blockers. Thromboembolic events occurred in 10 (5.6%) patients, 15 (8.3%) were re-explored, 4 (2.2%) had postoperative dialysis and 6 (3.3%) patients died by 30 days postoperation (Tables 2-4 ).
Thromboembolic adverse events
5 Seven patients had CVA, 2 had MI and 1 had PE (Tables 3 and 4) .
Five predictors for TAEs were identified through univariable analysis: the use of rFVIIa, female sex, isolated CABG surgery (with no additional valve surgery), preoperative left ventricular ejection fraction lower than 40% and preoperative dialysis (Supplementary 10 Material, Table S2 ). Multivariable regression model confirmed rFVIIa to be the only independent factor associated with the development of TAEs (Table 5 ). Two of the CVA patients had hemiplegia but they were able to recover acceptable mobility after 4 months. Three patients had mono-paresis that was completely recovered 15 in a few weeks. The remaining 2 patients had some disorientation 
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ADULT CARDIAC 3 A.M. Habib et al. / Interactive CardioVascular and Thoracic Surgery and speech problems. Two patients experienced MI as confirmed by echo-and electrocardiogram, along with significant troponin release. Coronary angiography was carried out, which revealed a new obstruction in the obtuse marginal artery in 1 patient and in 5 the left anterior descending artery in the second one, both distally to the anastomoses. Percutaneous coronary intervention stenting was successfully performed in both cases with clinical and functional improvement, and they were successfully discharged.
The patient who developed PE showed significant hypoxia 10 with echocardiographic signs of right ventricular strain after the rFVIIa dose. Pulmonary CT angiogram revealed an obstruction in the right middle lobar pulmonary artery. The patient received thrombolytic therapy and showed a considerable clinical improvement. A further pulmonary CT scan, 24 h afterwards, 15 showed partial opening of the occluded artery so the patient was transferred to the ward. Bleeding Fifteen (8.3%) patients were re-explored for bleeding according to our management protocol. rFVIIa, female sex, preoperative dialysis, preoperative anticoagulation treatment, emergency surgery, redo surgery, EuroSCORE II and CPB time in minutes were 30 identified as predictors for re-exploration in the univariable analysis (Supplementary Material, Table 3 ). However, multivariable analysis failed to confirm any of them as independent predictors of re-exploration (Table 6 ). Chest tube output was significantly lower in patients who received rFVIIa between 3 and 12 h after CSICU admission (Table  3 ). Blood product transfusions during the first 24 h after CSICU admission were significantly lower in patients receiving rFVIIa 5 compared to the conventional treatment group (Table 4) .
DISCUSSION
In this retrospective analysis, rFVIIa was found to be the only independent predictor of the development of TAEs, which was associated with significantly higher CSICU and hospital LOS. 10 Von Heymann et al. [6] was the first to report the use of rFVIIa for a case of refractory bleeding after a redo CABG with no TAEs detected. Many data analyses and systemic reviews [7, 8, 18, 19] have evaluated rFVIIa safety in general post-cardiac surgery populations, including CABG patients, with mixed results. These re- 15 ports did not advise its prophylactic use as it did not improve mortality but can raise the risk for thromboembolic events.
A higher incidence of TAEs was found in the rFVIIa group compared to the conventionally treated group, and this result is in agreement with other studies [20] [21] [22] [23] . However, our TAE rate 20 seems to be similar to the rate reported in the literature for patients who did not receive rFVIIa [22, 23] . An interesting point has to be emphasized in our series: most of the patients (72%) received a full dose (90-120 mg/kg), which is likely to increase the incidence of TAEs, and even patients receiving a half dose (40-25 50 mg/kg) exceeded the lowest dose reported in the literature.
The incidence of TAEs in this report was higher in CABG patients (9.9%) compared to the general cardiac surgery population receiving rFVIIa (5.5-5.9%) [20, 21] . Conversely, the TAE rate in the conventionally treated CABG group who did not receive 30 rFVIIa (2%) was comparable to that reported in the general population (2.4%) [20] . However, the mechanisms underlying this difference in terms of TAEs between the CABG population and the general cardiac surgery population are not clear and deserve further investigation.
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The European Multicentre Study on Coronary Artery Bypass Grafting (E-CABG) [24] should be able to provide us with more details about the use of rFVIIa after isolated CABG and its relationship with the development of stroke, MI, and other TAEs.
Furthermore, as shown by Mayer et al. [22] , the majority of the 40 newly developed TAEs in this report were CVA (70%). Moreover, Ponschab et al. [23] showed that the use of rFVIIa was associated with an increased rate of stroke in the rFVIIa group compared to the control arm. In this study, 20.4% of the study population had preoperative CVA, which increases their risk for another CVA. In 5 addition, carotid duplex was only performed preoperatively in selected patients. Regarding bleeding, our results are in agreement with other published studies [25, 26] . The chest tube output continued to be significantly high in the conventional treatment group until 10 9-12 h after the admission.
A decrease in surgical re-exploration for bleeding was found in the rFVIIa group [27, 28] . A meta-analysis of 5 clinical trials assessing a total of 298 patients revealed no significant decrease in surgical re-exploration for bleeding [25] . In 2011, this same group 15 showed [23] that the use of rFVIIa was associated with an insignificant reduction in terms of surgical re-exploration rate. Surprisingly, Chapman et al. [29] , who retrospectively analysed the safety profile and efficacy of rFVIIa used for bleeding following cardiac surgery, showed that the rFVIIa group had a higher 20 rate of re-operation for bleeding (11% vs 4%) and also required increased traditional blood product administration.
Limitations
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There are some limitations to this study: firstly, it was a retrospective study so the findings may be affected by unmeasured con-25 founders. Secondly, according to hospital policies, rFVIIa administration does not need to involve the clinical pharmacist or the haematologist. It can be easily prescribed by the surgeon, anaesthesiologist or intensivist. In addition, many cardiac surgeons, anaesthesiologist and intensivists have been involved in 30 this long study, which may have led to variations in their triggers for administration of rFVIIa. This makes it a subjective decision that may vary depending on the attending physician. Thirdly, blood tests and radiographic studies to confirm the diagnosis of TAEs were not done for all patients who received rFVIIa but only 35 following suspected clinical signs and symptoms. This might lead to missed TAEs. If these were routinely done for all patients who received rFVIIa, we would have a definitive picture of rFVIIa safety. Fourthly, carotid duplex was only done preoperatively in selected patients, but if routinely done it could have identified 40 patients at risk. Fifthly, the low rate of TAEs makes valid statistical analysis difficult, hence the wide confidence intervals. Finally, there was no long-term follow-up for the patients who received rFVIIa beyond CSICU discharge except for those with TAEs and readmissions.
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On the other hand, this is one of few reports to look into the safety of rFVIIa in post-CABG bleeding. Our patient population was more homogeneous than in other published studies and patients were treated according to our standard protocol for management of postoperative bleeding.
CONCLUSIONS
Post-CABG bleeding patients treated with rFVIIa exhibited significantly rapid control of chest tube bleeding and fewer blood product transfusions. However, rFVII was the only independent predictor identified for the development of TAEs. 55 Our results showed that rFVIIa is an effective treatment to control persistent bleeding in the postoperative cardiac surgery setting. However, because of the risk of serious complications, we advise restricting its use to the following situations:
Persistent bleeding that is not controlled in spite of: rFVIIa should not be used as an alternative to re-exploration nor by surgeons to buy some time before re-exploration. It is advised to avoid its use in patients bleeding post-CABG and extracorporeal membrane oxygenation patients.
Further prospective randomized studies are needed to clarify 70 the safety of rFVIIa in these patients. Meanwhile, the use of rFVIIa in such patients should be with extreme caution.
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